Details of the Drug

General Information of Drug (ID: DMKFQJP)

• Drug Name: Triflupromazine
• Synonyms: Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN)

Indication

Disease Entry	ICD 11	Status	REF
Nausea	MD90	Approved	[1]
Psychotic disorder	6A20-6A25	Approved	[2]
Vomiting	MD90	Approved	[1]
Schizophrenia	6A20	Withdrawn from market	[3]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[4]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[4]

• Therapeutic Class: Antipsychotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 352.4
  Logarithm of the Partition Coefficient (xlogp); 5.2
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 6
• Chemical Identifiers:
  Formula: C18H19F3N2S
  IUPAC Name: N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine
  Canonical SMILES: CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F
  InChI: InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
  InChIKey: XSCGXQMFQXDFCW-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5568
  ChEBI ID: CHEBI:9711
  CAS Number: 146-54-3
  DrugBank ID: DB00508
  TTD ID: D05NOS
  VARIDT ID: DR01359
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Antagonist	[5]
HUMAN clathrin-mediated endocytosis (RME)	TTAIY2U	.	Inhibitor	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[7]

Molecular Expression Atlas of This Drug

• The Studied Disease: Nausea
• ICD Disease Classification: MD90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
5-HT 2B receptor (HTR2B)	DTT	HTR2B	2.12E-02	-0.22	-0.9
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.42E-01	-4.36E-02	-2.21E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.80E-01	2.46E-01	2.41E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Triflupromazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[8]

Coadministration of a Drug Treating the Disease Different from Triflupromazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[9]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Midostaurin.	Acute myeloid leukaemia [2A60]	[10]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Idarubicin.	Acute myeloid leukaemia [2A60]	[10]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[10]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Arn-509.	Acute myeloid leukaemia [2A60]	[11]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[12]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Triflupromazine and Oliceridine.	Acute pain [MG31]	[13]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[8]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Memantine.	Alzheimer disease [8A20]	[8]
Galantamine	DMEO794	Moderate	Antagonize the effect of Triflupromazine when combined with Galantamine.	Alzheimer disease [8A20]	[15]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Triflupromazine when combined with Rivastigmine.	Alzheimer disease [8A20]	[15]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Triflupromazine and Metronidazole.	Amoebiasis [1A36]	[16]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[17]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Ivabradine.	Angina pectoris [BA40]	[11]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Dronedarone.	Angina pectoris [BA40]	[10]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Amyl nitrite.	Angina pectoris [BA40]	[17]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Nifedipine.	Angina pectoris [BA40]	[17]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[8]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Cilostazol.	Arterial occlusive disease [BD40]	[10]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Posaconazole.	Aspergillosis [1F20]	[10]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Levalbuterol.	Asthma [CA23]	[19]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Terbutaline.	Asthma [CA23]	[20]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Pirbuterol.	Asthma [CA23]	[19]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Salbutamol.	Asthma [CA23]	[19]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Formoterol.	Asthma [CA23]	[20]
Lisdexamfetamine	DM6W8V5	Moderate	Antagonize the effect of Triflupromazine when combined with Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[21]
Desipramine	DMT2FDC	Moderate	Increased plasma concentrations of Triflupromazine and Desipramine due to competitive inhibition of the same metabolic pathway.	Attention deficit hyperactivity disorder [6A05]	[22]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[10]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[10]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Triflupromazine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[10]
Linezolid	DMGFPU2	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Linezolid.	Bacterial infection [1A00-1C4Z]	[24]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[10]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Retigabine.	Behcet disease [4A62]	[25]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Cariprazine.	Bipolar disorder [6A60]	[8]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Triflupromazine and Loperamide.	Bowel habit change [ME05]	[26]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Eribulin.	Breast cancer [2C60-2C6Y]	[10]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Lapatinib.	Breast cancer [2C60-2C6Y]	[10]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[10]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Toremifene.	Breast cancer [2C60-2C6Y]	[10]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Bosutinib.	Breast cancer [2C60-2C6Y]	[11]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Triflupromazine when combined with Acetylcholine.	Cataract [9B10]	[27]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[28]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[29]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[29]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[29]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Triflupromazine and Dihydrocodeine.	Chronic pain [MG30]	[13]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Oxaliplatin.	Colorectal cancer [2B91]	[10]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Isoproterenol.	Conduction disorder [BC63]	[19]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Olopatadine.	Conjunctiva disorder [9A60]	[30]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Halothane.	Corneal disease [9A76-9A78]	[10]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Propofol.	Corneal disease [9A76-9A78]	[31]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Sevoflurane.	Corneal disease [9A76-9A78]	[10]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Triflupromazine and Remifentanil.	Corneal disease [9A76-9A78]	[32]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Clofazimine.	Crohn disease [DD70]	[33]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Pasireotide.	Cushing syndrome [5A70]	[10]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Sertraline.	Depression [6A70-6A7Z]	[10]
Trimipramine	DM1SC8M	Moderate	Increased plasma concentrations of Triflupromazine and Trimipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[22]
Nortriptyline	DM4KDYJ	Moderate	Increased plasma concentrations of Triflupromazine and Nortriptyline due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[22]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Triflupromazine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[34]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Selegiline.	Depression [6A70-6A7Z]	[24]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Isocarboxazid.	Depression [6A70-6A7Z]	[24]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Escitalopram.	Depression [6A70-6A7Z]	[10]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Tranylcypromine.	Depression [6A70-6A7Z]	[35]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and OPC-34712.	Depression [6A70-6A7Z]	[8]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Phenelzine.	Depression [6A70-6A7Z]	[24]
Clomipramine	DMINRKW	Moderate	Increased plasma concentrations of Triflupromazine and Clomipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[22]
Amoxapine	DMKITQE	Moderate	Increased plasma concentrations of Triflupromazine and Amoxapine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[22]
Doxepin	DMPI98T	Moderate	Increased plasma concentrations of Triflupromazine and Doxepin due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[36]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Maprotiline.	Depression [6A70-6A7Z]	[8]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Esketamine.	Depression [6A70-6A7Z]	[16]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Nitroglycerin.	Diabetic foot ulcer [BD54]	[17]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Mepenzolate.	Digestive system disease [DE2Z]	[14]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Oxybutynine.	Discovery agent [N.A.]	[8]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Triflupromazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[37]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Meclizine.	Dizziness and giddiness [MB48]	[8]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Triflupromazine and Deutetrabenazine.	Dystonic disorder [8A02]	[38]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Ingrezza.	Dystonic disorder [8A02]	[39]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Triflupromazine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[40]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Triflupromazine when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[41]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Guanabenz.	Essential hypertension [BA00]	[42]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Phenoxybenzamine.	Essential hypertension [BA00]	[17]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Nicardipine.	Essential hypertension [BA00]	[17]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Nadolol.	Essential hypertension [BA00]	[17]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Solifenacin.	Functional bladder disorder [GC50]	[10]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Tolterodine.	Functional bladder disorder [GC50]	[8]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Pentamidine.	Fungal infection [1F29-1F2F]	[10]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Triflupromazine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[43]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Phentolamine.	Gangrene [MC85]	[17]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Propantheline.	Gastric ulcer [DA60]	[8]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[10]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Triflupromazine when combined with Pilocarpine.	Glaucoma [9C61]	[27]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Eplerenone.	Heart failure [BD10-BD1Z]	[17]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Carvedilol.	Heart failure [BD10-BD1Z]	[17]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[16]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Furosemide.	Heart failure [BD10-BD1Z]	[16]
Amiloride	DMRTSGP	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Amiloride.	Heart failure [BD10-BD1Z]	[17]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Bumetanide.	Heart failure [BD10-BD1Z]	[16]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[16]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Procarbazine.	Hodgkin lymphoma [2B30]	[24]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[45]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[17]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Eprosartan.	Hypertension [BA00-BA04]	[17]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Acebutolol.	Hypertension [BA00-BA04]	[17]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Moexipril.	Hypertension [BA00-BA04]	[17]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Bisoprolol.	Hypertension [BA00-BA04]	[17]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Captopril.	Hypertension [BA00-BA04]	[17]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Trandolapril.	Hypertension [BA00-BA04]	[17]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Methyldopa.	Hypertension [BA00-BA04]	[17]
Clonidine	DM6RZ9Q	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Clonidine.	Hypertension [BA00-BA04]	[17]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Losartan.	Hypertension [BA00-BA04]	[17]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Nebivolol.	Hypertension [BA00-BA04]	[17]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Levamlodipine.	Hypertension [BA00-BA04]	[17]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Doxazosin.	Hypertension [BA00-BA04]	[17]
Verapamil	DMA7PEW	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Verapamil.	Hypertension [BA00-BA04]	[17]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Triflupromazine and TAK-491.	Hypertension [BA00-BA04]	[17]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Pindolol.	Hypertension [BA00-BA04]	[17]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Fenoldopam.	Hypertension [BA00-BA04]	[17]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Indapamide.	Hypertension [BA00-BA04]	[16]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Benazepril.	Hypertension [BA00-BA04]	[17]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Labetalol.	Hypertension [BA00-BA04]	[17]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Diazoxide.	Hypertension [BA00-BA04]	[17]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Perindopril.	Hypertension [BA00-BA04]	[17]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Felodipine.	Hypertension [BA00-BA04]	[17]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Quinapril.	Hypertension [BA00-BA04]	[17]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Telmisartan.	Hypertension [BA00-BA04]	[17]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Irbesartan.	Hypertension [BA00-BA04]	[17]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Hydralazine.	Hypertension [BA00-BA04]	[17]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Lisinopril.	Hypertension [BA00-BA04]	[17]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[16]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[17]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Amantadine.	Influenza [1E30-1E32]	[47]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and ITI-007.	Insomnia [7A00-7A0Z]	[8]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[10]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Clidinium.	Irritable bowel syndrome [DD91]	[8]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Dicyclomine.	Irritable bowel syndrome [DD91]	[8]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Triflupromazine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[15]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Crizotinib.	Lung cancer [2C25]	[48]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Triflupromazine and Porfimer Sodium.	Lung cancer [2C25]	[49]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Ceritinib.	Lung cancer [2C25]	[10]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Osimertinib.	Lung cancer [2C25]	[50]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Selpercatinib.	Lung cancer [2C25]	[51]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Chloroquine.	Malaria [1F40-1F45]	[52]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[52]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Primaquine.	Malaria [1F40-1F45]	[10]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[11]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[53]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Vemurafenib.	Melanoma [2C30]	[10]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and LGX818.	Melanoma [2C30]	[54]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[55]
Propranolol	DM79NTF	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Propranolol.	Migraine [8A80]	[17]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Lasmiditan.	Migraine [8A80]	[56]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Flibanserin.	Mood disorder [6A60-6E23]	[57]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Panobinostat.	Multiple myeloma [2A83]	[58]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Thalidomide.	Multiple myeloma [2A83]	[11]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Siponimod.	Multiple sclerosis [8A40]	[16]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Fingolimod.	Multiple sclerosis [8A40]	[10]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Ozanimod.	Multiple sclerosis [8A40]	[59]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Triflupromazine and Methoxsalen.	Mycosis fungoides [2B01]	[16]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Romidepsin.	Mycosis fungoides [2B01]	[25]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[10]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[60]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Triflupromazine when combined with Dextroamphetamine.	Narcolepsy [7A20]	[21]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Dimenhydrinate.	Nausea/vomiting [MD90]	[8]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Promethazine.	Nausea/vomiting [MD90]	[8]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Triflupromazine and Metoclopramide.	Nausea/vomiting [MD90]	[61]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Dolasetron.	Nausea/vomiting [MD90]	[10]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Ondansetron.	Nausea/vomiting [MD90]	[10]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Entrectinib.	Non-small cell lung cancer [2C25]	[11]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Triflupromazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[21]
Amfepramone	DM9YSNQ	Moderate	Antagonize the effect of Triflupromazine when combined with Amfepramone.	Obesity [5B80-5B81]	[21]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Triflupromazine and Lorcaserin.	Obesity [5B80-5B81]	[62]
Benzphetamine	DMIJATC	Moderate	Antagonize the effect of Triflupromazine when combined with Benzphetamine.	Obesity [5B80-5B81]	[21]
Metolazone	DMB39LO	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Metolazone.	Oedema [MG29]	[16]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Polythiazide.	Oedema [MG29]	[16]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Apraclonidine.	Optic nerve disorder [9C40]	[63]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Rucaparib.	Ovarian cancer [2C73]	[10]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Triflupromazine and Pentazocine.	Pain [MG30-MG3Z]	[32]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Triflupromazine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[64]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Triflupromazine and Butorphanol.	Pain [MG30-MG3Z]	[32]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Triflupromazine and Oxymorphone.	Pain [MG30-MG3Z]	[32]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Triflupromazine and Levorphanol.	Pain [MG30-MG3Z]	[32]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Flavoxate.	Pain [MG30-MG3Z]	[8]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Triflupromazine and Nalbuphine.	Pain [MG30-MG3Z]	[32]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Triflupromazine when combined with Methamphetamine.	Pain [MG30-MG3Z]	[65]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Triflupromazine and Hydrocodone.	Pain [MG30-MG3Z]	[32]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Triclabendazole.	Parasitic worm infestation [1F90]	[25]
Safinamide	DM0YWJC	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Safinamide.	Parkinsonism [8A00]	[24]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Triflupromazine when combined with Pergolide.	Parkinsonism [8A00]	[66]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Triflupromazine when combined with Opicapone.	Parkinsonism [8A00]	[67]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Rasagiline.	Parkinsonism [8A00]	[24]
Biperiden	DME78OA	Moderate	Antagonize the effect of Triflupromazine when combined with Biperiden.	Parkinsonism [8A00]	[68]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Triflupromazine when combined with Levodopa.	Parkinsonism [8A00]	[66]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Pimavanserin.	Parkinsonism [8A00]	[69]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Orphenadrine.	Parkinsonism [8A00]	[8]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Methylscopolamine.	Peptic ulcer [DA61]	[8]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Famotidine.	Peptic ulcer [DA61]	[16]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[70]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Lefamulin.	Pneumonia [CA40]	[9]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Degarelix.	Prostate cancer [2C82]	[11]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Triflupromazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[71]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Nilutamide.	Prostate cancer [2C82]	[11]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Enzalutamide.	Prostate cancer [2C82]	[11]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Bicalutamide.	Prostate cancer [2C82]	[11]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Terazosin.	Prostate hyperplasia [GA90]	[17]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Tamsulosin.	Prostate hyperplasia [GA90]	[17]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Silodosin.	Prostate hyperplasia [GA90]	[17]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[72]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Triflupromazine when combined with Neupro.	Restless legs syndrome [7A80]	[66]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Quetiapine.	Schizophrenia [6A20]	[10]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Mesoridazine.	Schizophrenia [6A20]	[16]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Thioridazine.	Schizophrenia [6A20]	[73]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Aripiprazole.	Schizophrenia [6A20]	[8]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Iloperidone.	Schizophrenia [6A20]	[10]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Paliperidone.	Schizophrenia [6A20]	[10]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Perphenazine.	Schizophrenia [6A20]	[8]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Molindone.	Schizophrenia [6A20]	[8]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Thiothixene.	Schizophrenia [6A20]	[8]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Risperidone.	Schizophrenia [6A20]	[8]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Amisulpride.	Schizophrenia [6A20]	[74]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Asenapine.	Schizophrenia [6A20]	[10]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Pimozide.	Schizophrenia [6A20]	[11]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Triflupromazine and Fentanyl.	Sensation disturbance [MB40]	[32]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Triflupromazine and Sufentanil.	Sensation disturbance [MB40]	[32]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[10]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[10]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[10]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[11]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[10]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Pitolisant.	Somnolence [MG42]	[10]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[10]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[10]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Cabozantinib.	Thyroid cancer [2D10]	[11]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Triflupromazine and Papaverine.	Tonus and reflex abnormality [MB47]	[17]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Triflupromazine and Tizanidine.	Tonus and reflex abnormality [MB47]	[75]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Tacrolimus.	Transplant rejection [NE84]	[10]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Atropine.	Unspecific substance harmful effect [NE6Z]	[8]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[8]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[8]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Triflupromazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[14]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[10]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[10]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Triflupromazine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[10]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Triflupromazine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[10]

References

• [1] Triflupromazine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4330).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
• [5] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [6] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [7] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [8] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [9] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [10] Canadian Pharmacists Association.
• [11] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [12] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [13] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [14] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [15] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [16] Cerner Multum, Inc. "Australian Product Information.".
• [17] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [18] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [19] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [20] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [21] Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
• [22] Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
• [23] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [24] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [25] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
• [26] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [27] Multum Information Services, Inc. Expert Review Panel.
• [28] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [29] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [30] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [31] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [32] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [33] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [34] Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
• [35] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
• [36] Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
• [37] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [38] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [39] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [40] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [41] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [42] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [43] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [44] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [45] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [46] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [47] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [48] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [49] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [50] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [51] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [52] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [53] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [54] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [55] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [56] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [57] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [58] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [59] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [60] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [61] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [62] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [63] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [64] Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
• [65] Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
• [66] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [67] Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
• [68] Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3. [PMID: 6021058]
• [69] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [70] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [71] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [72] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [73] El-Yousef MK, Manier DH "Tricyclic antidepressants and phenothiazines." JAMA 229 (1974): 1419. [PMID: 4152942]
• [74] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [75] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.